vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and CareCloud, Inc. (CCLD). Click either name above to swap in a different company.

CareCloud, Inc. is the larger business by last-quarter revenue ($34.4M vs $19.2M, roughly 1.8× Apyx Medical Corp). On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 21.9%). CareCloud, Inc. produced more free cash flow last quarter ($6.6M vs $-2.8M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 15.1%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

CareCloud, Inc. is a publicly traded American healthcare information technology company that provides services, to healthcare providers and hospitals. The Company maintains its headquarters in Somerset, New Jersey, and employs approximately 4,000 workers worldwide.

APYX vs CCLD — Head-to-Head

Bigger by revenue
CCLD
CCLD
1.8× larger
CCLD
$34.4M
$19.2M
APYX
Growing faster (revenue YoY)
APYX
APYX
+12.9% gap
APYX
34.7%
21.9%
CCLD
More free cash flow
CCLD
CCLD
$9.4M more FCF
CCLD
$6.6M
$-2.8M
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
15.1%
CCLD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
APYX
APYX
CCLD
CCLD
Revenue
$19.2M
$34.4M
Net Profit
$-1.3M
Gross Margin
62.6%
Operating Margin
0.1%
9.1%
Net Margin
-6.8%
Revenue YoY
34.7%
21.9%
Net Profit YoY
71.9%
EPS (diluted)
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
CCLD
CCLD
Q4 25
$19.2M
$34.4M
Q3 25
$12.9M
$31.1M
Q2 25
$11.4M
$27.4M
Q1 25
$9.4M
$27.6M
Q4 24
$14.2M
$28.2M
Q3 24
$11.5M
$28.5M
Q2 24
$12.1M
$28.1M
Q1 24
$10.2M
$26.0M
Net Profit
APYX
APYX
CCLD
CCLD
Q4 25
$-1.3M
Q3 25
$-2.0M
$3.1M
Q2 25
$-3.8M
$2.9M
Q1 25
$-4.2M
$1.9M
Q4 24
$-4.6M
Q3 24
$-4.7M
$3.1M
Q2 24
$-6.6M
$1.7M
Q1 24
$-7.6M
$-241.0K
Gross Margin
APYX
APYX
CCLD
CCLD
Q4 25
62.6%
Q3 25
64.4%
Q2 25
62.3%
Q1 25
60.1%
Q4 24
63.0%
Q3 24
60.5%
Q2 24
61.7%
Q1 24
58.1%
Operating Margin
APYX
APYX
CCLD
CCLD
Q4 25
0.1%
9.1%
Q3 25
-6.5%
10.3%
Q2 25
-22.6%
10.9%
Q1 25
-32.4%
7.3%
Q4 24
-21.4%
12.2%
Q3 24
-31.6%
11.4%
Q2 24
-45.7%
8.1%
Q1 24
-64.6%
0.5%
Net Margin
APYX
APYX
CCLD
CCLD
Q4 25
-6.8%
Q3 25
-15.4%
9.8%
Q2 25
-33.2%
10.6%
Q1 25
-44.0%
7.0%
Q4 24
-32.5%
Q3 24
-40.9%
10.9%
Q2 24
-54.0%
6.0%
Q1 24
-74.0%
-0.9%
EPS (diluted)
APYX
APYX
CCLD
CCLD
Q4 25
$0.06
Q3 25
$0.04
Q2 25
$0.04
Q1 25
$-0.04
Q4 24
$0.00
Q3 24
$-0.04
Q2 24
$-0.19
$-0.14
Q1 24
$-0.22
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
CCLD
CCLD
Cash + ST InvestmentsLiquidity on hand
$31.7M
Total DebtLower is stronger
$37.5M
$1.2M
Stockholders' EquityBook value
$14.5M
$59.5M
Total Assets
$66.8M
$87.6M
Debt / EquityLower = less leverage
2.58×
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
CCLD
CCLD
Q4 25
$31.7M
Q3 25
$25.1M
Q2 25
$29.3M
Q1 25
$31.0M
Q4 24
$31.7M
Q3 24
$28.0M
Q2 24
$32.7M
Q1 24
$37.3M
Total Debt
APYX
APYX
CCLD
CCLD
Q4 25
$37.5M
$1.2M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$37.5M
$336.0K
Q3 24
$37.5M
Q2 24
Q1 24
Stockholders' Equity
APYX
APYX
CCLD
CCLD
Q4 25
$14.5M
$59.5M
Q3 25
$5.8M
$57.8M
Q2 25
$7.3M
$56.1M
Q1 25
$10.5M
$54.2M
Q4 24
$14.2M
$49.8M
Q3 24
$11.0M
$46.5M
Q2 24
$14.7M
$43.2M
Q1 24
$20.3M
$41.4M
Total Assets
APYX
APYX
CCLD
CCLD
Q4 25
$66.8M
$87.6M
Q3 25
$57.4M
$90.6M
Q2 25
$58.2M
$75.2M
Q1 25
$60.2M
$73.6M
Q4 24
$64.8M
$71.6M
Q3 24
$60.7M
$70.7M
Q2 24
$65.4M
$74.0M
Q1 24
$70.7M
$76.9M
Debt / Equity
APYX
APYX
CCLD
CCLD
Q4 25
2.58×
0.02×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
2.64×
0.01×
Q3 24
3.40×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
CCLD
CCLD
Operating Cash FlowLast quarter
$-2.5M
$8.7M
Free Cash FlowOCF − Capex
$-2.8M
$6.6M
FCF MarginFCF / Revenue
-14.6%
19.0%
Capex IntensityCapex / Revenue
1.4%
6.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.1M
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
CCLD
CCLD
Q4 25
$-2.5M
$8.7M
Q3 25
$-3.5M
$7.4M
Q2 25
$-1.2M
$7.4M
Q1 25
$-702.0K
$5.1M
Q4 24
$-2.9M
$5.2M
Q3 24
$-4.4M
$7.1M
Q2 24
$-4.3M
$4.3M
Q1 24
$-6.3M
$4.1M
Free Cash Flow
APYX
APYX
CCLD
CCLD
Q4 25
$-2.8M
$6.6M
Q3 25
$-4.1M
$6.5M
Q2 25
$-1.5M
$6.2M
Q1 25
$-757.0K
$4.5M
Q4 24
$-3.2M
$4.3M
Q3 24
$-4.6M
$6.7M
Q2 24
$-4.6M
$4.2M
Q1 24
$-6.4M
$3.8M
FCF Margin
APYX
APYX
CCLD
CCLD
Q4 25
-14.6%
19.0%
Q3 25
-31.5%
20.9%
Q2 25
-13.2%
22.8%
Q1 25
-8.0%
16.2%
Q4 24
-22.4%
15.2%
Q3 24
-40.0%
23.6%
Q2 24
-38.0%
14.8%
Q1 24
-62.2%
14.5%
Capex Intensity
APYX
APYX
CCLD
CCLD
Q4 25
1.4%
6.2%
Q3 25
4.0%
2.8%
Q2 25
2.3%
4.2%
Q1 25
0.6%
2.3%
Q4 24
1.7%
3.3%
Q3 24
1.3%
1.2%
Q2 24
2.4%
0.5%
Q1 24
0.3%
1.1%
Cash Conversion
APYX
APYX
CCLD
CCLD
Q4 25
Q3 25
2.41×
Q2 25
2.55×
Q1 25
2.62×
Q4 24
Q3 24
2.26×
Q2 24
2.56×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APYX
APYX

Segment breakdown not available.

CCLD
CCLD

Healthcare IT$31.0M90%
Medical Practice Management$3.4M10%

Related Comparisons